DOCSMEDIUM SIGNALOPPORTUNITY10-K

Doximity delivered strong operational performance with 20% revenue growth and substantially higher profitability while reducing share repurchases.

The company's ability to expand its physician user base to over 620,000 active providers while maintaining healthy margins demonstrates the strength of its platform and market position. The reduced share buyback activity suggests management may be prioritizing cash retention or alternative capital allocation strategies, which could indicate preparation for growth investments or changing market conditions.

Comparing 2025-05-20 vs 2024-05-23View on EDGAR →
FINANCIAL ANALYSIS

Doximity showed solid financial performance with revenue growing 20% to $570.4M and gross profit expanding 21.1% to $514.5M, while operating income increased 39% and net income grew substantially. Operating cash flow strengthened notably to $273.3M, though share buybacks declined significantly from $280.7M to $120.3M. The balance sheet remained healthy with total assets growing 17.1% to $1.3B and stockholders equity expanding over 20% to $1.1B.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-57.1%
$280.7M→$120.3M

Buyback activity reduced 57.1% — capital being redeployed elsewhere or cash conservation underway.

Net Income
P&L
+51.2%
$147.6M→$223.2M

Net income grew 51.2% — bottom-line growth signals improving overall business health.

Operating Cash Flow
Cash Flow
+48.4%
$184.1M→$273.3M

Operating cash flow surged 48.4% — exceptional cash generation, highest quality earnings signal.

Operating Income
P&L
+39%
$163.9M→$227.8M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Accounts Receivable
Balance Sheet
+26.7%
$101.3M→$128.4M

Receivables grew 26.7% — monitor days sales outstanding for collection efficiency.

Gross Profit
P&L
+21.1%
$424.8M→$514.5M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Stockholders Equity
Balance Sheet
+20.1%
$901.4M→$1.1B

Equity base grew 20.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
+20%
$475.4M→$570.4M

Revenue growing 20% — solid top-line momentum, watch margins for quality of growth.

Current Assets
Balance Sheet
+19.2%
$912.9M→$1.1B

Current assets grew 19.2% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+17.1%
$1.1B→$1.3B

Asset base grew 17.1% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-05-20
PRIOR — 2024-05-23
ADDED
The registrant had outstanding 136,906,542 shares of Class A common stock and 50,919,611 shares of Class B common stock as of May 13, 2025.
Management's Discussion and Analysis of Financial Condition and Results of Operations 46 Item 7A.
That guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians and their colleagues.
Doximity puts modern software in the hands of physicians and other medical professionals.
Our focus on physician-centric product design and clinical productivity has led to high levels of adoption and endorsement by these healthcare professionals.
For example, we had more than 620,000 unique active providers use our clinical workflow tools in the quarter ended March 31, 2025.
Our business model is designed to both respect and support our members while driving value for our customers through our Marketing, Hiring, and Workflow Solutions (as defined below).
Our revenue-generating customers, primarily pharmaceutical manufacturers and health systems, have access to a suite of commercial solutions that benefit from broad usage by physicians and other medical professionals.
Our Workflow Solutions, which include our telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and easily connect with patients and colleagues.
This also drives greater value for our pharmaceutical and health system customers seeking to interact with specific groups of physicians and other medical professionals.
REMOVED
The registrant had outstanding 122,999,951 shares of Class A common stock and 62,425,902 shares of Class B common stock as of May 16, 2024.
Management's Discussion and Analysis of Financial Condition and Results of Operations 47 Item 7A.
That guiding principle has enabled Doximity to become an essential and trusted professional platform for physicians.
Doximity s physician cloud puts modern software in the hands of physicians and other medical professionals.
Our focus on physician-centric product design and clinical productivity has led to high levels of adoption and endorsement by health care professionals.
For example, we had more than 580,000 unique active providers use our clinical workflow tools in the quarter ended March 31, 2024.
Our business model is designed to both respect and support physicians while driving value for our customers through our Marketing, Hiring, and Productivity Solutions (as defined below).
Our revenue-generating customers, primarily pharmaceutical manufacturers and health systems, have access to a suite of commercial solutions that benefit from broad physician usage.
Our Productivity Solutions, which include our telehealth, on-call scheduling, and AI-supported medical correspondence tools, are designed to help clinicians streamline their clinical workflow and easily connect with patients and colleagues.
This also drives greater value for our pharmaceutical and health system customers seeking to interact with specific groups of physicians.
MORE OPPORTUNITY SIGNALS
ABTHIGHAbbott announced a major strategic acquisition of Exact Sciences Corporation to ...
2026-02-20
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →